

=> fil hcaplu
FILE 'HCAPLUS' ENTERED AT 09:17:19 ON 17 JUL 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 17 Jul 2003 VOL 139 ISS 3
FILE LAST UPDATED: 16 Jul 2003 (20030716/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d stat que
L1 26 SEA FILE=HCAPLUS ABB=ON (.TAUER C?) OR (TAUER,C?) OR (TAUER,
C?)/AU, IN
L2 3831 SEA FILE=HCAPLUS ABB=ON ((MEYER H?) OR (MEYER,H?) OR (MEYER,
H?)/AU, IN
L3 40 SEA FILE=HCAPLUS ABB=ON ((MITTERER A?) OR (MITTERER,A?) OR
(MITTERER, A?)/AU, IN
L4 127 SEA FILE=HCAPLUS ABB=ON ((BARRETT N?) OR (BARRETT,N?) OR
(BARRETT, N?)/AU, IN
L5 4014 SEA FILE=HCAPLUS ABB=ON L1 OR L2 OR L3 OR L4
L6 7 SEA FILE=HCAPLUS ABB=ON L5 AND (HEPATITIS(W)A OR HAV)

=> d ibib abs hitrn 16 1-7

L6 ANSWER 1 OF 7 HCAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2003:472410 HCAPLUS
TITLE: Method of production of purified hepatitis
A virus particles, and their use in vaccine
preparation
INVENTOR(S): Tauer, Christa; Meyer, Heidi; Mitterer,
Artur; Barrett, Noel
PATENT ASSIGNEE(S): Baxter Healthcare S.A., Switz.
SOURCE: PCT Int. Appl., 40 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003049766	A2	20030619	WO 2002-EP14008	20021210
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,			

GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
 LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
 PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ,
 UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD,
 RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG,
 CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,
 PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
 MR, NE, SN, TD, TG

US 2003124511 A1 20030703 US 2001-6205 20011210

PRIORITY APPLN. INFO.: US 2001-6205 A 20011210

AB The present invention provides methods of purifn. of **hepatitis A** virus (**HAV**) from the supernatant of an infected cell culture by filtering and virus inactivation treatment and prodn. of a prepn. of purified **HAV** antigen under serum-free conditions. Contaminating impurities which might derive from the cells or the cell culture medium are efficiently removed by the method of invention. The invention is also directed to an **HAV** vaccine compn. comprising a prepn. consisting of purified mature **HAV** particles in an amt. sufficient to induce a protective immune response. The vaccine of present invention was compared in regards to its immunogenicity with 2 com. vaccines (VAQTA 50U and HAVRIX 1440). The antibody titers of the pooled sera of mice given the undiluted vaccine of invention at 15-20 IU/mL were 3541 mIU/mL compared to 2541 mIU/mL and 691 mIU/mL when given undiluted VAQTA and HAVRIX, resp.

L6 ANSWER 2 OF 7 HCPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2003:454904 HCPLUS

DOCUMENT NUMBER: 139:21090

TITLE: Large scale production of **Hepatitis**

A virus in microcarrier bound Vero cells

INVENTOR(S): Meyer, Heidi; Reiter, Manfred; Mundt, Wolfgang; Barrett, Noel; Dorner, Friedrich

PATENT ASSIGNEE(S): Austria

SOURCE: U.S. Pat. Appl. Publ., 11 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003108861	A1	20030612	US 2001-6882	20011210
WO 2003049767	A2	20030619	WO 2002-EP14012	20021210
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.: US 2001-6882 A 20011210

AB The present invention provides methods of large scale prodn. of **Hepatitis A** Virus (**HAV**) on Vero cells bound to

microcarrier. The invention also provides for methods of isolation of HAV from the cell culture supernatant of HAV infected VERO cells.

L6 ANSWER 3 OF 7 HCPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 1999:565945 HCPLUS
 DOCUMENT NUMBER: 131:204586
 TITLE: Method for the elimination of pathogens from solutions containing proteins
 INVENTOR(S): Barrett, Noel; Dorner, Friedrich; Linnau, Yendra; Poelsler, Gerhard; Schwarz, Hans-Peter; Teschner, Wolfgang
 PATENT ASSIGNEE(S): Immuno Aktiengesellschaft, Austria
 SOURCE: PCT Int. Appl., 20 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9943362	A1	19990902	WO 1999-AT46	19990224
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AT 9800341	A	20000215	AT 1998-341	19980225
AT 406873	B	20001025		
AU 9925028	A1	19990915	AU 1999-25028	19990224
PRIORITY APPLN. INFO.:			AT 1998-341	A 19980225
			WO 1999-AT46	W 19990224

AB Pathogens are eliminated from a soln. contg. plasma proteins by filtration. The soln. is incubated in the presence of an inorg., particulate, surface-active detergent (e.g. a filter aid such as Aerosil) and filtered in a deep-bed filter to obtain a clear soln. Thus, a 2.5% Ig soln. contg. parvovirus B19 was treated with Aerosil 380 (15 mg/g protein) for 1 h at room temp. and filtered through a CUNO SA90 filter to reduce the virus titer to <101.7.

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 4 OF 7 HCPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 1999:9735 HCPLUS
 DOCUMENT NUMBER: 130:71519
 TITLE: Process for reducing the concentration of viral and molecular pathogens in a biological material and its application to blood products
 INVENTOR(S): Eibl, Johann; Dorner, Friedrich; Barrett, Noel; Poelsler, Gerhard; Linnau, Yendra
 PATENT ASSIGNEE(S): Immuno Aktiengesellschaft, Austria
 SOURCE: PCT Int. Appl., 16 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9857672	A2	19981223	WO 1998-AT143	19980610
WO 9857672	A3	19990318		
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AT 9701029	A	20000515	AT 1997-1029	19970613
AT 407159	B	20010125		
AU 9877500	A1	19990104	AU 1998-77500	19980610
AU 726808	B2	20001123		
EP 988063	A2	20000329	EP 1998-925314	19980610
EP 988063	B1	20020828		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI				
EP 1004323	A1	20000531	EP 2000-100420	19980610
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI				
BR 9810098	A	20000808	BR 1998-10098	19980610
JP 2002505674	T2	20020219	JP 1999-503396	19980610
AT 222778	E	20020915	AT 1998-925314	19980610
ES 2181227	T3	20030216	ES 1998-925314	19980610
AT 9900952	A	20001015	AT 1999-952	19990528
AT 407744	B	20010525		
NO 9906118	A	20000210	NO 1999-6118	19991210
MX 9911516	A	20000531	MX 1999-11516	19991210
AU 726999	B2	20001130	AU 1999-64478	19991213
AU 9964478	A1	20000224		
NO 2000003584	A	20000210	NO 2000-3584	20000712
US 2002018985	A1	20020214	US 2001-934330	20010820
US 6465170	B2	20021015		

PRIORITY APPLN. INFO.:

AT 1997-1029	A	19970613
EP 1998-925314	A3	19980610
WO 1998-AT143	W	19980610
US 2000-445862	A1	20000518

AB The invention concerns the decontamination of biol. materials by reducing the concn. of viral and mol. pathogens in a manner that the biol. material is mixed with an org. solvent and brought in contact with an ion exchanger; pathogens are adsorbed onto the exchanger; at least one of the target materials is not adsorbed or only slightly adsorbed. The biol. materials are e.g. blood, blood fractions; target substances are IgGs, blood coagulation factors; the org. solvent is an alc., e.g. ethanol; the ion exchanger is a DEAE-type, e.g. DEAE-Sephadex. The process can be performed in a batch mode or in a flow-through mode; for sepn. of the used adsorbent, filtration can be applied. Thus to IgG contg. Cohn II+III fraction, 10-14% ethanol was added and the soln. was cooled between -3.degree.C and -1.degree.C; the soln. was spiked with various viruses. For each gram of protein 0.5 g of DEAE-Sephadex A-50 was stirred in; pH was set to 6.2. After 6 h of stirring the slurry was filtrated. The yield of IgG was >70%; the virus content was measured by virus titrn. or

PCR; the removal of viruses was substantial.

L6 ANSWER 5 OF 7 HCPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 1997:740140 HCPLUS
 DOCUMENT NUMBER: 128:7298
 TITLE: Biological material free of viral and molecular pathogens and process for its production
 INVENTOR(S): Barrett, Noel; Eibl, Johann; Dorner, Friedrich; Poelsler, Gerhard; Haemmerle, Thomas
 PATENT ASSIGNEE(S): Immuno Aktiengesellschaft, Austria; Barrett, Noel; Eibl, Johann; Dorner, Friedrich; Poelsler, Gerhard; Haemmerle, Thomas
 SOURCE: PCT Int. Appl., 50 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9740861	A1	19971106	WO 1997-AT75	19970423
W: AU, CA, IL, JP, NO, US				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AT 9600780	A	19970715	AT 1996-780	19960430
AT 403477	B	19980225		
AU 9725612	A1	19971119	AU 1997-25612	19970423
AU 731048	B2	20010322		
EP 900089	A1	19990310	EP 1997-917167	19970423
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2000510107	T2	20000808	JP 1997-538394	19970423
NO 9804979	A	19981223	NO 1998-4979	19981026
PRIORITY APPLN. INFO.:			AT 1996-780	A 19960430
			WO 1997-AT75	W 19970423

AB Biol. material is freed from or depleted in pathogens, esp. viral pathogens, by contacting it with a ligand or receptor which reacts with a receptor or ligand of the pathogen, thereby producing a ligand/receptor complex, and sepn. of the ligand/receptor complex by a process which separates the complexed pathogen partially or completely from the biol. material. Thus, hepatitis A virus was 100% removed from a soln. of human serum albumin by addn. of a human antibody to hepatitis A virus, followed by tangential-flow filtration for 4 h through a 35-nm nanofilter.

L6 ANSWER 6 OF 7 HCPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 1997:684302 HCPLUS
 DOCUMENT NUMBER: 127:351168
 TITLE: Process for disintegrating nucleic acids and preparing biological products of guaranteed quality
 INVENTOR(S): Dorner, Friedrich; Barrett, Noel; Eibl, Johann
 PATENT ASSIGNEE(S): Immuno A.-G., Austria; Dorner, Friedrich; Barrett, Noel; Eibl, Johann
 SOURCE: PCT Int. Appl., 70 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9737686	A1	19971016	WO 1997-AT68	19970408
W: CA, JP, US				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AT 9600629	A	20000115	AT 1996-629	19960409
AT 406778	B	20000925		
EP 900087	A1	19990310	EP 1997-915196	19970408
EP 900087	B1	20021009		
R: AT, BE, CH, DE, ES, FR, GB, IT, LI, NL				
AT 225669	E	20021015	AT 1997-915196	19970408
ES 2185003	T3	20030416	ES 1997-915196	19970408
US 6165711	A	20001226	US 1998-155758	19981118
PRIORITY APPLN. INFO.:			AT 1996-629	A 19960409
			WO 1997-AT68	W 19970408
AB A biol. active material is exposed .gtoreq.1 time to a laser beam (.ltoreq.0.1 J/cm ²) to disintegrate the entire biol. active nucleic acid in the material, while the biol. integrity and activity of the biol. material are retained. Contaminating nucleic acids and viruses can thus be destroyed by laser irradn., optionally in the presence of a photosensitizer, in therapeutic biol. products such as vaccines produced in mammalian cell cultures. The quality of the product, in terms of absence of contaminating nucleic acid, is verified by use of a nucleic acid amplification assay such as laser-induced fluorescence-PCR. Thus, a recirculating system is described in which a virus-contg. suspension can be inactivated by repeated exposure to laser radiation in a tube or cuvette with a glass window. HIV-1, tick-borne encephalitis virus, influenza virus, and herpes simplex virus 1 were inactivated by 10 cycles of exposure to radiation from a He-Ne laser at 633 nm and 10 mW in the presence of 2 .mu.M methylene blue. Poliovirus was relatively resistant, being fully inactivated by this treatment only at 30 .mu.M methylene blue.				

L6 ANSWER 7 OF 7 HCPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1996:440965 HCPLUS

DOCUMENT NUMBER: 125:84835

TITLE: Method for producing biologicals in protein-free culture

INVENTOR(S): Kistner, Otfried; Barrett, Noel; Mundt, Wolfgang; Dorner, Friedrich

PATENT ASSIGNEE(S): Immuno Aktiengesellschaft, Austria

SOURCE: PCT Int. Appl., 97 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 4

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9615231	A2	19960523	WO 1995-EP4439	19951110
WO 9615231	A3	19960801		
W: CA, FI, JP, NO, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US 5753489	A	19980519	US 1995-487046	19950607
US 5756341	A	19980526	US 1995-483522	19950607
EP 791055	A1	19970827	EP 1995-937888	19951110
R: AT, BE, CH, DE, DK, ES, FR, GB, IE, IT, LI, NL, SE				

JP 10503093	T2	19980324	JP 1995-515726	19951110
FI 9701998	A	19970509	FI 1997-1998	19970509
PRIORITY APPLN. INFO.:			US 1994-338761	A 19941110
			US 1995-483522	A 19950607
			US 1995-487046	A 19950607
			US 1995-487222	A 19950607
			WO 1995-EP4439	W 19951110

AB The present invention includes an approach for producing viruses, such as influenza, and vaccines derived therefrom as well as recombinant proteins derived from viral vectors, by utilizing vertebrate cells cultured under protein-free conditions. These cells, which include a cellular biomass, show improved capabilities for propagating viruses and eliminate the need for costly and time-consuming viral passaging and purifn. The invention also includes further approaches for enhancing the propagation of viruses by employing activating substances, modifying the activation site of viruses, and using augmentation loops. Improved approaches for producing viral reassortants also are provided.